Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Abbott Laboratories (ABT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 121,135,800
  • Shares Outstanding, K 1,754,320
  • Annual Sales, $ 27,390 M
  • Annual Income, $ 477,000 K
  • 36-Month Beta 1.48
  • Price/Sales 4.41
  • Price/Cash Flow 14.37
  • Price/Book 3.92

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 0.74
  • Number of Estimates 10
  • High Estimate 0.75
  • Low Estimate 0.73
  • Prior Year 0.66
  • Growth Rate Est. (year over year) +12.12%

Price Performance

See More
Period Period Low Period High Performance
1-Month
64.48 +7.09%
on 08/22/18
69.25 -0.29%
on 09/21/18
+4.30 (+6.64%)
since 08/21/18
3-Month
60.31 +14.48%
on 06/25/18
69.25 -0.29%
on 09/21/18
+7.30 (+11.82%)
since 06/21/18
52-Week
51.50 +34.08%
on 09/22/17
69.25 -0.29%
on 09/21/18
+17.62 (+34.26%)
since 09/21/17

Most Recent Stories

More News
Landmark Study Shows Treatment with Abbott's MitraClip® is Superior to Medical Therapy for Advanced Heart Failure Patients with Significant Secondary Mitral Regurgitation

Abbott (NYSE: ABT) today announced positive clinical study results from a randomized controlled trial comparing treatment with the MitraClip® device to guideline-directed medical therapy in select patients...

ABT : 69.05 (+0.38%)
Abbott Banks on New Approvals and Buyouts, Competition Rife

Abbott's (ABT) receipt of FDA approval for XIENCE Sierra coronary stent system as well as a reimbursement approval in Japan for the same device will help it revive the dull Vascular business.

ABT : 69.05 (+0.38%)
ATHN : 136.60 (-1.51%)
VEEV : 103.91 (+0.81%)
ISRG : 556.77 (-0.79%)
Muscle Relaxant Drugs - Global Markets to 2024: Abbott Labs, Medtronic, Johnson & Johnson, Endo Pharma, and more are Profiled - ResearchAndMarkets.com

The "Muscle Relaxants Drugs Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024" report has been added to ResearchAndMarkets.com's offering.

ABT : 69.05 (+0.38%)
JNJ : 142.88 (+0.63%)
MDT : 97.85 (+0.38%)
Global Genetic Testing Market Outlook 2022 with Profiles of Abbott Labs, Roche Diagnostics, Myriad Genetics, Thermo Fisher Scientific, Hologic, Cepheid, Agilent Technologies and QIAGEN

The "Global Genetic Testing Market Outlook 2022" report has been added to ResearchAndMarkets.com's offering.

A : 70.72 (-0.58%)
ABT : 69.05 (+0.38%)
CPHD : 52.95 (unch)
MYGN : 46.27 (-2.32%)
Global Rapid Microbiology Testing Market 2018-2023: Major Players Profiled Include bioMrieux, Abbott Laboratories, Danaher, and Becton, Dickinson and Co

https://mma.prnewswire.com/media/732750/Research_and_Markets.jpg

ABT : 69.05 (+0.38%)
Medical - Products Stock Outlook: Short-Term Pain Inevitable

Medical - Products Stock Outlook: Short-Term Pain Inevitable

ABT : 69.05 (+0.38%)
SRDX : 72.80 (unch)
ICUI : 265.50 (-0.09%)
QDEL : 64.84 (-5.19%)
Top Analyst Reports for Walmart, IBM & Texas Instruments

Top Analyst Reports for Walmart, IBM & Texas Instruments

LMT : 337.66 (+1.36%)
ABT : 69.05 (+0.38%)
WFC : 54.99 (-1.01%)
IBM : 151.35 (+0.13%)
TXN : 110.05 (+1.44%)
WMT : 95.90 (+0.16%)
ABT or PETQ: Which Is the Better Value Stock Right Now?

ABT vs. PETQ: Which Stock Is the Better Value Option?

ABT : 69.05 (+0.38%)
PETQ : 41.61 (+0.97%)
Here's Why You Should Add Abbott (ABT) to Your Portfolio Now

Abbott (ABT) continues to deliver strong and consistent performance in all segments. The company has also been hogging the limelight within Diabetic Care on progress with its FreeStyle Libre.

ABT : 69.05 (+0.38%)
AMED : 118.55 (-0.84%)
MASI : 122.50 (+0.41%)
ISRG : 556.77 (-0.79%)
Cyber Attack Fears Grip MedTech: 3 Safe Stocks

In the wake of rising incidences of cyber attacks in the MedTech space, we have zeroed down on some stocks which at present are safe-havens for investors.

ABT : 69.05 (+0.38%)
FLGT : 3.29 (-1.35%)
ATHN : 136.60 (-1.51%)
HMSY : 31.99 (-0.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade ABT with:

Business Summary

Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. They have a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.

See More

Key Turning Points

2nd Resistance Point 69.43
1st Resistance Point 69.24
Last Price 69.05
1st Support Level 68.87
2nd Support Level 68.69

See More

52-Week High 69.25
Last Price 69.05
Fibonacci 61.8% 62.47
Fibonacci 50% 60.38
Fibonacci 38.2% 58.28
52-Week Low 51.50

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar